JMJD7

Across TCGA pan-cancer cohorts, JMJD7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JMJD7 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher JMJD7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated JMJD7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where JMJD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	1.000	0.562	.005	35	view →
HNSC	DFS	Median	III,IV	0.767	0.495	.004	34	view →
LUAD	OS	Median	II,III,IV	0.423	0.934	.008	12	view →
GBM	DFS	Tertile	All	0.529	0.260	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JMJD7–CCRCC (OS)

Open the CCRCC breakdown →